Searchable abstracts of presentations at key conferences in endocrinology

ea0041ep994 | Thyroid (non-cancer) | ECE2016

Sorafenib-induced changes in thyroid hormone levels in patients with hepatocellular carcinoma

Beukhof Carolien , Bins Sander , van Doorn Leni , de Herder Wouter , Visser Theo , Mathijssen Ron , Peeters Robin

Background: Recent studies suggest enhanced peripheral thyroid hormone metabolism as an explanation for the changes in thyroid hormone levels in patient treated with Sorafenib.Methods: In this single centre, prospective, observational cohort study 60 patients with hepatocellular carcinoma were treated with Sorafenib. Thyroid stimulating hormone (TSH) and free thyroxine (FT4) were measured at baseline (time-0), at 6 weeks (time-1) and at the end of therap...

ea0073aep592 | Reproductive and Developmental Endocrinology | ECE2021

Spuriously high testosterone concentrations testosterone gel users: A marker for detection

Schaper Sophie , Wiepjes Chantal , den Heijer Martin , Beukhof Carolien , Heijboer Annemieke C

ContextContamination of collected blood samples by application of testosterone gel near the venipuncture site can cause spuriously elevated serum testosterone concentrations. Often this will be detected only in case of extreme discrepancies between lab result and clinical effects. Because in vitro testosterone cannot be metabolized as the testosterone in vivo we hypothesized that measuring estradiol, as a metabolite of testosterone after aromati...

ea0056gp230 | Thyroid Cancer - Diagnostics & Treatments | ECE2018

Peptide receptor radionuclide therapy in patients with medullary thyroid carcinoma: predictors and pitfalls

Beukhof Carolien , Brabander Tessa , van Nederveen Francien , van Velthuysen Loes , van Kemenade Folkert , de Rijke Yolanda , Froberg Lideke , Kam Boen , de Herder Wouter , Peeters Robin

Aim: To evaluate the effectiveness of Peptide Receptor Radionuclide Therapy with 177Lu-octreotate (PRRT) for medullary thyroid carcinoma (MTC).Background: There are few therapeutic options for progressive metastatic MTC. The Erasmus MC Center for Neuroendocrine Tumors has been at the forefront of developing PRRT for neuroendocrine tumors. PRRT has also been suggested to be a useful treatment for MTC, but evidence is very limited.<p class="...